Last reviewed · How we verify

Intradialytic parenteral nutrition

EZUS-LYON 1 · FDA-approved active Small molecule

Intradialytic parenteral nutrition (IDPN) delivers intravenous amino acids, dextrose, and lipids directly into the bloodstream during hemodialysis sessions to supplement nutritional intake in malnourished dialysis patients.

Intradialytic parenteral nutrition (IDPN) delivers intravenous amino acids, dextrose, and lipids directly into the bloodstream during hemodialysis sessions to supplement nutritional intake in malnourished dialysis patients. Used for Protein-energy malnutrition in hemodialysis patients, Nutritional supplementation in end-stage renal disease patients unable to meet nutritional requirements orally.

At a glance

Generic nameIntradialytic parenteral nutrition
SponsorEZUS-LYON 1
Drug classNutritional supplement / parenteral nutrition formulation
ModalitySmall molecule
Therapeutic areaNephrology / Renal disease
PhaseFDA-approved

Mechanism of action

IDPN is administered through the venous line of the dialysis circuit during treatment, allowing simultaneous delivery of macronutrients while waste removal occurs. This approach bypasses the gastrointestinal tract and provides concentrated nutrition to patients with inadequate oral intake or protein-energy wasting, a common complication of end-stage renal disease. The timing during dialysis optimizes nutrient delivery while minimizing additional vascular access requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: